Table 5 Drugs with serendipitous off-target effects on cognition and memory
Drug name | Main indication | Positive side effect on cognition and memory | Study subjects/design | Supporting evidence (PMID) | Target protein in core DHN |
|---|---|---|---|---|---|
Bexarotene (Targretin) | Skin cancer | Rapid reversal of cognition, social and olfactory deficits | Mouse model of AD | 22323736 | RXRA |
RXRB | |||||
Tamoxifen | Breast cancer | Higher level of independence in activities of daily life and decision making; relationship of tamoxifen with a lower prevalence of AD | Cross-sectional study of women receiving tamoxifen | 11005221 | ESR1 |
Raloxifene | Breast cancer | Reduced risk of cognitive impairment in postmenopausal women | The Multiple Outcomes of Raloxifene Evaluation (MORE) randomized, placebo-controlled trial amonf postmenopausal women with osteoporosis | 15800139 | ESR1 |
Vorinostat | Cutaneous T cell lymphoma (skin cancer) | Complete restoration of contextual memory | Mutant APPswe/PS1dE9 mice | 20010553 | HDAC2 |
HDAC3 | |||||
Lovastatin | Hyperlipidemia | Reduction of Abeta formation and slowing the progression of AD | Double-blind randomized study on human subjects | 11900994 | HDAC2 |
Resveratrol | Aging | Promoting clearance of Abeta peptides | Various cell lines | 16162502 | CSNK2A1 |
Sorafenib | Renal cell carcinoma | Reversal of memory impairment | Transgenic APPswe mouse model | 20201822 | BRAF |
Naloxone | Opioid overdose | Improvement of learning and memory through enhancement of long-term potentiation | Aged rats with declined memory | 14670637 | CREB1 |
| Â | Â | Â | Â | 15805661 | Â |